Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Update WT

<< Previous

Bullboard Posts

Next >>

Comment by Amazighon Jul 30, 2021 5:19am

141 Views

Post# 33630875

RE:RE:RE:Update WT

Red~One wrote: That article says "The exercise price of the warrants will remain the same." I thought the exercise price for 1 post split share would be 20x as well .065 would become the exercise price of $1.30 for the B's and .155 x 20 would be $3.10 for the A's plus you need to supply 20 warrants at whatever you paid for them. So am I wrong? Will I be able to buy a post split share with 20 warrants and .065?

For each of the 20 warrants the exercise price is $0.065. So, if you exercise 20 warrants, then you have to pay 20 x 0.065= $1.30, and will get 1 share for it. It is as if you bought the one share for $1.30 . I hope this clears things up

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec